Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Open accessThe DOI matches its Crossref record; 265 of the 268 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, SLNs utilize receptor-mediated and adsorptive-mediated transcytosis to cross the BBB and enable sustained drug release [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SLNs can effectively transport drugs across the BBB, enabling the delivery of compounds that are otherwise impermeable [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759 · cited 3×
“These features make SLNs advantageous for production on a large industrial scale [43].”
InfluentialSacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569 · cited 1×
“There are several types of ischemic strokes, such as lacunar, cardioembolic, and cryptogenic strokes, and hemorrhagic strokes [259].”
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150 · cited 2×
“SLNs can also be synthesized by ultrasonication [120,170,173] (Figure 7) in an easily assessable way, to overcome the limitations of high-shear homogenization.”
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · cited 1×
“The essential neurovascular unit cell types that contribute to the functionality of the BBB are endothelial cell adhesion molecules, pericytes, smooth muscle cells, astrocytes, and micro glia, etc., which form the BBB, a complex barrier unit [13–16].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death
Choi, D. W., & Rothman, S. M. (1990) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.13.030190.001131 · Cited by 2,223
Animal Communication: When I’m Calling You, Will You Answer Too?
Vickers, N. J. (2017) · Current Biology · doi:10.1016/j.cub.2017.05.064 · Cited by 2,210
Research works printed but not linked: 8
- Dingler A. Feste Lipid-Nanopartikel als Kolloidale Wirkstoffträgersysteme zur Dermalen Applikation Ph.D. Thesis Freie Universität Berlin Berlin, Germany 1998
- Müller R. Schwarz C. Zur Mühlen A. Mehnert W. Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles (SLN) Proceedings of International Symposium on Controlled Release of Bioactive Materials Nice, France 27–30 June 1994 146 147 · DOI · Paper page
- Zur Mühlen A. Mehnert W. Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles Pharmazie 1998 53 552 555 9704911
- zur Muhlen A. Feste Lipid Nanopartikel mit Prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und Mechanismen Ph.D. Thesis Free University of Berlin Berlin, Germany 1996
- Meyer W. Wettkampf und Spiel in den Miniaturen der Manessischen Liederhandschrift Stadion 1988 14 1 48
- Nelluri S. Felix J. Sathesh K. Formulation and evaluation of galantamine nanoparticles for neurological disorders Int. J. Pharm. Chem. Biol. Sci. 2015 5 63 70
- Özdemir Y.G. Pehlivan S.B. Sekerdag E. Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery Across the Blood–Brain Barrier Academic Press Cambridge, MA, USA 2017
- Duarte A.M.G. Resveratrol and Grape’s Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson’s and Alzheimer’s Diseases Master’s Thesis Faculty of Engineering of University of Porto Porto, Portugal 2015
Cited by
Items 101–200 of 319
Hocaoğlu, R., Zıkşahna, K., & Ihlamur, M. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00026-8 · Cited by 15
Nanostructured Lipid Carriers: A Potential Era of Drug Delivery Systems
Chinthaginjala, H., Bogavalli, V., Hindustan, A. A., Pathakamuri, J., Pullaganti, S. S., Gowni, A., & Baktha, B. (2023) · Indian Journal of Pharmaceutical Education and Research · doi:10.5530/ijper.58.1.3 · Cited by 27
Khan, S., Bano, N., Ahamad, S., Dar, N. J., Nazir, A., & Bhat, S. A. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216206 · Cited by 14
Rohani, M., Nemattalab, M., Hedayati, M. A., Ghasemi, S., & Hesari, Z. (2023) · Physica Scripta · doi:10.1088/1402-4896/acf3a5 · Cited by 13
Damavandi, A. R., Mirmosayyeb, O., Ebrahimi, N., Zalpoor, H., Khalilian, P., Yahiazadeh, S., Eskandari, N., Rahdar, A., Kumar, P. S., & Pandey, S. (2022) · Applied Nanoscience · doi:10.1007/s13204-022-02698-x · Cited by 12
Li, Q., Tang, Z., Zhang, Y., Yuan, T., Yuan, B., Du, L., & Jin, Y. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123191 · Cited by 14
Innovation in nanomedicine: nanocarriers for central nervous system disorders management
Waqar, M. A., Mubarak, N., Khan, A. M., Ahmad, S., Zaib, M., Kanwal, U., Khan, I. N., Ayesha, M., Mughal, M., & Fahad, M. (2024) · International Journal of Polymeric Materials · doi:10.1080/00914037.2024.2399271 · Cited by 14
“Additional benefits of constructing treatments in solid lipid nanoparticles (SLN) include improved protein stability, prevention of proteolytic degradation, and prolonged (controlled or regulated) dissociation of the integrated molecules [102] .”
Evolution of lipid nanoparticles as charioteers of Alzheimer's disease therapeutics
Chakraborty, B., Patel, G., Padhan, B., Das, J., & Patel, M. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102442 · Cited by 18
Narayan, S., Gupta, P. K., & Nagpal, K. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00062 · Cited by 13
Nanoparticle-Based Delivery Systems for Synergistic Therapy in Lung Cancers
Deng, Z., Siraj, A. A., Lowry, I., Ruan, E., Patel, R., Gao, W., Kalin, T. V., & Kalinichenko, V. V. (2025) · Bioengineering · doi:10.3390/bioengineering12090968 · Cited by 17
“The solid core acts as a sustained-release reservoir, enabling gradual drug diffusion for prolonged therapeutic effects [73,74].”
"Nanomedicine and Nano Formulations for Neurodegenerative Diseases"
Pathak, Y. V. (2022) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2022.42.006713 · Cited by 11
Nanocarrier Mediated Intranasal Drug Delivery Systems for the Management of Parkinsonism: A Review
Kapoor, A., Hafeez, A., & Kushwaha, P. (2023) · Current Drug Delivery · doi:10.2174/1567201820666230523114259 · Cited by 10
Jiang, M., Zhang, G., Yu, Y., Zhao, Y., Liu, J., Zeng, Q., Feng, M.-Y., Ye, F., Xiong, D.-S., Wang, L. S., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02602-5 · Cited by 10
“They are mainly used as controlled-and sustained-release drug carriers [119, 120], gene therapy [121, 122], artificial tissue and organ construction [123], vaccine development [124], and anticancer drug delivery [125], and have the advantages of good biocompatibility and biodegradability, high…”
Backgrounddu Preez, H. N., Lin, J., Maguire, G. E. M., Aldous, C. M., & Kruger, H. G. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14296 · Cited by 13
Targeting the lung tumour stroma: harnessing nanoparticles for effective therapeutic interventions
Zhang, S., & Wang, H. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2410462 · Cited by 10
“Biologically, SlNs can enhance drug bioavailability due to their tiny size and capacity to infiltrate various obstacles like the blood-brain barrier [100].”
Vengadesan, D., Arumugam, N., Manikandan, E., & Mandal, A. (2024) · BioNanoScience · doi:10.1007/s12668-024-01773-7 · Cited by 10
“In vitro–related studies on DTX-loaded SLN conjugated with lactoferrin using carbodiimide chemistry suggest that Tf-DTX-has more potential to deliver drugs than DTX-SLN [79].”
Teleanu, R. I., Moldoveanu, E.-T., Niculescu, A.-G., Predescu, E., Roza, E., Ţincu, I. F., Grumezescu, A. M., & Teleanu, D. M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060707 · Cited by 11
Advancements in Nanotherapeutics for the Treatment of Depression via Intranasal Pathway: A Review
Patel, M. B., Minglani, V. V., Vaddadi, H., Jha, L. L., Patel, L., Huanbutta, K., & Sangnim, T. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s525759 · Cited by 19
Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier
Sharma, H., Narayanan, K. B., Ghosh, S., Singh, K. K., Rehan, P., Amist, A. D., Bhaskar, R., & Sinha, J. K. (2025) · Biomimetics · doi:10.3390/biomimetics10010025 · Cited by 11
“Solid lipid nanoparticles (SLNs), a type of organic nanoparticle, are composed of a lipid core surrounded by a surfactant layer, and they are known for their stability and biodegradability [26].”
InfluentialTiwary, P., Oswal, K., Varghese, R., Anchan, H., & Gupta, P. K. (2025) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2025.105510 · Cited by 13
Ahmed, S., Gozal, D., & Khalyfa, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110316 · Cited by 10
Nanomedicine-enabled neuroprotection: therapeutic role of berberine in neurodegenerative diseases
Pal, B., Panda, S., Bashir, B., Vishwas, S., Chaitanya, M., Hussain, M. S., Gupta, G., Kumbhar, P., Gupta, S. K., & Singh, S. K. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11193-9 · Cited by 10
“They also present multiple benefits such as evasion of the reticuloendothelial system (RES), less systemic toxicity, sustained or controlled release of drug in time, and the ability to be designed to be manufactured at scale at relatively low cost [102]. brain targeting [105].”
De, R., Shi, S., & Kim, K. (2025) · Advanced Science · doi:10.1002/advs.202517004 · Cited by 20
Senousy, M. A., Eid, A. H., Zaki, M. B., Abd‐Elmawla, M. A., Ghaiad, H. R., El‐Shiekh, R. A., Ahmed, S., & Khalifa, H. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1794983 · Cited by 10
“Solid lipid nanoparticles (SLNs), typically ranging from 10 to 1,000 nm, are biocompatible lipid-based nanocarriers made of fatty acids, waxes, or triglycerides (Satapathy et al., 2021).”
Manicum, A.-L. E., Sargazi, S., Razzaq, S., Kumar, G. V., Rahdar, A., Zeybekler, S. E., Ain, Q. U., Bilal, M., & Aboudzadeh, M. A. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103288 · Cited by 9
Pandi, J. S., Pavadai, P., Sundar, L. M., Murugesan, S., Theivendren, P., Pandian, S. R. K., & Kunjiappan, S. (2024) · Journal of Cluster Science · doi:10.1007/s10876-024-02751-5 · Cited by 9
Tiwary, P., Oswal, K., Varghese, R., & Gupta, P. K. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115122 · Cited by 13
Strategies and methods of nanocrystal technology for targeting drug delivery
Xue, L., Ding, J., Liu, Y., Ma, Y., Yang, C., Wang, W., & Wang, Y. (2024) · Journal of Nanoparticle Research · doi:10.1007/s11051-024-06025-z · Cited by 9
“Therefore, when the nanoparticle size is reduced below 200 nm, the circulation time of the nanoparticles could be increased, thus increasing the contact with the BBB [72].”
Self-citationLipid Nanocarriers as Precision Delivery Systems for Brain Tumors
Keshari, R., Dewani, M., Kaur, N., Patel, G. K., Singh, S. K., Chandra, P., Prasad, R., & Srivastava, R. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00007 · Cited by 8
A Path of Novelty from Nanoparticles to Nanobots: Theragnostic Approach for Targeting Cancer Therapy
Kaur, G., Khanna, B., Yusuf, M., Sharma, A., Khajuria, A., Alajangi, H. K., Jaiswal, P. K., Sachdeva, M. S., Barnwal, R. P., & Singh, G. (2023) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2023046674 · Cited by 8
A REVIEW ON SOLID LIPID NANOPARTICLES
RAJ, R., Kolay, A., & Havelikar, U. A. (2023) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2023v15i5.3051 · Cited by 8
“ There may be a potential of drug ejection during SLN storage as a result of polymeric transformation [21].”
BackgroundHalder, S., Nasrin, F., Shill, M. C., Shuma, M. L., Sultan, M. Z., & Reza, M. S. (2025) · Scientifica · doi:10.1155/sci5/9034181 · Cited by 10
Recent advancement of fisetin-based nanoformulations in the management of psoriasis
Telrandhe, U. B., Hasnain, A. N., Kothawade, S. N., & Telange, D. R. (2025) · Discover Nano · doi:10.1186/s11671-025-04298-4 · Cited by 9
“[43] due to its poor aqueous solubility (10.45 μg/ml) [27] and high lipophilicity (log P 3.2) [43].”
InfluentialKuznetsova, D. A., Kuznetsov, D. M., Gaynanova, G. A., Zueva, I. V., Babaev, V. M., Voloshina, A. D., Sibgatullina, G., Petrov, K. A., Zakharova, L. Y., & Sinyashin, O. G. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111678 · Cited by 7
Tiny Carriers, Big Impact: A Review of Nanomaterial Systems for β-Carotene Bioavailability
Pourmadadi, M., Ahmadi, H., Abdouss, M., Rahdar, A., & Pandey, S. (2024) · BioNanoScience · doi:10.1007/s12668-024-01374-4 · Cited by 8
Nashli, F. G., Aghajanpour, S., Farmoudeh, A., Balef, S. S. H., Torkamanian, M., Razavi, A., Irannejad, H., & Ebrahimnejad, P. (2025) · Journal of Microencapsulation · doi:10.1080/02652048.2024.2437362 · Cited by 7
“…rivar-oxaban can be effectively achieved through the use of SLNs. SLNs have been extensively investigated and used as a drug delivery system for improving drug solubility and absorption both in vitro and in vivo (Varshosaz et al. 2010, Ghasemiyeh and Mohammadi-Samani 2018, Satapathy et al. 2021).”
Jan, N., Madni, A., Shah, H., Khan, S., Ijaz, Q. A., Badshah, S. F., Ali, A., Khurshid, U., & Bostanudin, M. F. (2023) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-023-09753-2 · Cited by 8
Guo, Z., Qi, P., Pei, D., & Zhang, X. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103733 · Cited by 7
Bhati, H., Bansal, K., & Bajpai, M. (2024) · Current Pharmaceutical Analysis · doi:10.2174/0115734129344438240927100440 · Cited by 8
Kulkarni, M., Nadendla, K., Pai, A., Ashili, S., Maibach, H. I., & Manikkath, J. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106891 · Cited by 10
Inflammatory lung diseases: a clinical and scientific review of the latest advances and challenges
Katamesh, A. A., Almansour, K., Hassoun, S. M., Sayed, O. M., Break, M. K. B., Zaki, R. M., Afzal, O., & Radwan, A. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00749-y · Cited by 6
“They also pres-ent features like controlled release, the ability to incorporate both hydrophilic and lipophilic drugs, targeted release, simple manufacturing processes, controllable particle size, easy scalability, and reduced toxicity [93, 97, 99].”
InfluentialPlant-based flavonoids and their nanoparticles: Latest arsenal against Alzheimer’s disease
Kumbhar, P., Kolekar, K. A., Vishwas, S., Kamble, V., Bashir, B., Patil, K. S., Bhagwat, D. A., Gupta, G., Prasher, P., Singh, M., et al. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01906-9 · Cited by 10
“Furthermore, they offer superior stability to loaded therapeutics, making it an ideal choice for delivery of flavonoids in treating AD [132].”
Pathogenic breaches: how viruses compromise blood-tissue barriers
Apoorva, & Singh, S. K. (2025) · Tissue Barriers · doi:10.1080/21688370.2025.2549020 · Cited by 12
“271 SLNs additionally protects medicines from enzymatic degradation and enhance pharmacokinetics, making them ideal for CNS-targeted treatments.”
Bahuguna, R., Rehman, F., Awasthi, R., Babu, K. R., Akhter, M. H., Begum, M. Y., Kumar, D., Gupta, S. M., Singh, S., & Singh, P. A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107759 · Cited by 6
Bseiso, E. A., Sheta, N. M., & Abdel-Haleem, K. M. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2409807 · Cited by 6
“In addition, the required bioavailability is poor (Cingolani et al. 2000; Jankovic and Stacy 2007; Satapathy et al. 2021) with lower therapeutic efficacy.”
Neuro-Nanocarriers: Redefining Treatment Pathways for Brain Disorders
Chauhan, A., Mori, D., Soniwala, M. M., Prajapati, B. G., & Shah, S. R. (2024) · BioNanoScience · doi:10.1007/s12668-024-01730-4 · Cited by 7
“There may also be chances of drug expulsion following polymeric transition, and a higher ratio of water content is not favorable for SLN formulation [63].”
Nanoparticle-Based Therapies for Management of Subarachnoid Hemorrhage, Neurotrauma, and Stroke
Hey, G. E., Mehkri, I., Mehkri, Y., Maqbool, H., Tahirkheli, M., Woodford, S. J., & Lucke-Wold, B. P. (2024) · Biomedicines · doi:10.3390/biomedicines13010016 · Cited by 7
Mallamaci, R., Castellani, S., Francesca, L., Medaglia, P. G., Fracchiolla, G., Cardone, R. A., Guerra, L., Tripaldi, F., Porcelli, V., Muscella, A., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125399 · Cited by 6
(2022) · Biointerface Research in Applied Chemistry · doi:10.33263/briac131.024 · Cited by 7
“Another major advantage of these nanoparticulate lipospheres over other delivery systems is the potential for extended-release of entrapped drugs due to their solid lipid matrix [8].”
BackgroundSherif, A. Y., Harisa, G. I., & Alanazi, F. K. (2022) · Drug Delivery Letters · doi:10.2174/2210303113666221226092547 · Cited by 6
Manzoor, S. I., Ahanger, I. A., Kamli, M. R., Malik, M. A., & Dar, T. A. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148293 · Cited by 6
Emerging strategies to overcome chemotherapy resistance in breast cancer
Abouzeid, H. A., Liu, X., & Abuelhana, A. (2025) · Discover Medicine · doi:10.1007/s44337-025-00470-y · Cited by 6
“SLNs that carry PTX and curcumin suppress NF-κB signaling and trigger apoptosis in TNBC cells, which improves treat-ment response [108].”
Panday, A., Dixena, B., Vyas, A., & Jain, A. K. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.169329 · Cited by 6
Lipid-based nanostructures in targeted management of neurological disorders: A comprehensive review
Guleria, M., Kamble, A., Upadhyay, M., Sethi, P., Patel, M. B., Malhan, A., Rastogi, S., Datta, D., Singh, S. A., & Prajapati, B. G. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126530 · Cited by 8
The role of immunomodulatory nano systems in the treatment of sepsis: past, present, and future
Hossan, M. S., Gadelrab, H. A., Luo, M., Guo, D., Valenzuela-Faccini, N., & Luo, J. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2608357 · Cited by 5
Singh, G., & Narang, R. K. (2023) · Assay and Drug Development Technologies · doi:10.1089/adt.2023.059 · Cited by 5
Designing biomaterials for the treatment of autoimmune diseases
Tang, B., Xie, X., Lu, J., Huang, W., Yang, J., Tian, J., & Lei, L. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102278 · Cited by 10
Sharma, D., Gupta, A., Rawat, R., Sharma, S., Yadav, J. S., & Saxena, A. (2024) · Intelligent Pharmacy · doi:10.1016/j.ipha.2024.07.004 · Cited by 11
Vallianou, N. G., Dalamaga, Μ., Pavlou, A., Rebelos, E., Karamanolis, N. N., Papachristoforou, E., Mavrothalassitis, E., Eleftheriadou, I., Tentolouris, N., & Kounatidis, D. C. (2025) · Biomolecules · doi:10.3390/biom15050653 · Cited by 9
Advances in solid-lipid nanoparticle chemistry as drug delivery vehicles
Garg, G., Garg, S., Patel, P., Gupta, G. D., & Kurmi, B. D. (2024) · International Journal of Polymeric Materials · doi:10.1080/00914037.2024.2344603 · Cited by 7
“[33] The use of co-surfactants like glycocholate, tyloxapol, sodium taurodeoxycholate, or sodium dodecyl sulfate together with surfactants reduces particle size.”
Lipid nanocarriers encapsulating herbal drugs for brain diseases therapy
Gad, S., El-Gogary, R. I., Geneidi, A. S., & Hathout, R. M. (2023) · Archives of Pharmaceutical Sciences Ain Shams University · doi:10.21608/aps.2023.202432.1115 · Cited by 7
“…dysfunction, the buildup of misfolded proteins, neuroinflammation, aging, oxidative harm, and sometimes inherited and molecular issues, which can either occur separately or combined, leading to disruption of neuronal communication and thus long-term cognitive and motor impairment [1, 3, 4] .”
BackgroundInfluentialThe Application of Nanotechnology and Nanomaterials in Depression: An Updated Review
Yadav, K., Rani, A., Tyagi, P. K., & Babu, M. R. (2023) · Precision Nanomedicine · doi:10.33218/001c.82215 · Cited by 7
Roamcharern, N., & Yubolphan, R. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1810486 · Cited by 5
Biswal, B., Satapathy, B. S., Mishra, A., Maharana, L., & Pattnaik, S. (2025) · Current Drug Discovery Technologies · doi:10.2174/0115701638329824241220055621 · Cited by 4
Emerging nano-derived therapy for the treatment of dementia: a comprehensive review
Ahmad, S., Ahmad, L., Adil, M., Sharma, R., khan, S., Hasan, N., & Aqil, M. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01863-3 · Cited by 5
“Drugs are dissolved or distributed throughout the solid matrix of SLNs, a form of lipid nanocarrier system with a hydrophobic core and a monolayer of phospholipid covering [114].”
Lotfi, F., Nemattalab, M., & Hesari, Z. (2025) · Current Microbiology · doi:10.1007/s00284-025-04157-6 · Cited by 4
“…and food industries [11–13], due to its various advantages, including controlled release characteristics, lower toxicity compared to some polymeric nanoparticles, enhanced physicochemical stability of both hydrophilic and lipophilic substances, increased drug bioavailability, etc. [14–16].”
Novel Nanoformulations to Overcome Obstacles in Herbal Drug Delivery for Alzheimer's Disease
Kumar, D., Wal, P., Wal, A., Lari, M. Q., Ashesh, A. M., Kumar, D., Singh, S. K., Singh, B., & Kumar, A. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266362594250527112018 · Cited by 4
Kumar, S., Malviya, R., Sridhar, S. B., Wadhwa, T., & Shareef, J. (2026) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2026.110695 · Cited by 6
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 7
Ouyang, H., Hu, J., Qiu, X., Wu, S., Guo, F., & Tan, Y. (2022) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2022.2124521 · Cited by 4
“2018), passive membrane diffusion (Satapathy et al. 2021), efflux mediated transport (Pulgar 2019), carrier mediated transcytosis and receptor mediated transcytosis (Jones and Shusta 2007; SanchezCovarrubias et al.”
BackgroundMittal, P., & Hazari, P. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-96117-2.00009-1 · Cited by 5
An Update on Parkinson’s Disease and its Neurodegenerative Counterparts
Adam, H., Gopinath, S. C. B., Arshad, M. K. M., Adam, T., Subramanıam, S., & Hashim, U. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230403085733 · Cited by 5
Saadh, M. J., Shallan, M. A., Hussein, U. A., Mohammed, A. Q., Al-Shuwaili, S. J., Shikara, M. D., Ami, A. A., Khalil, N. A. M. A., Ahmad, I., Abbas, H. H., et al. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03033-7 · Cited by 5
“…drug delivery owing to their distinctive physical and chemical properties, ability to evade the reticuloendothelial system (RES), diminished systemic toxicity, controlled or prolonged drug release in a time-regulated fashion, and scalability in a cost-efficient manner (Satapathy et al. 2021).”
RetractedKhotimah, H., Rahmaniar, F. Z., Zahra, F. A., Anaqah, R., Kurniawan, S. N., Rahayu, M., & Sulistomo, H. W. (2024) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2024.26.3.0099 · Cited by 4
“The sustained release of drugs plays a vital role in epilepsy management, ensuring therapeutic drug levels within the brain, reducing seizures, and minimizing the need for frequent medication administration [37–39].”
Tonk, M., Singh, I., Sharma, R. J., & Chauhan, S. B. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128332345240823111524 · Cited by 3
Nanotechnology-driven approaches for the management of Huntington's disease
Shahrukh, M., Jiba, U., Khan, M. A., Amin, S., Ahmad, F. J., & Hasan, N. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107318 · Cited by 4
Alzheimer’s disease: unraveling role of xanthone derivatives and nanocarriers
Suhaili, I. N. A., Yow, H.-Y., Mah, S. H., Huri, H. Z., & Tan, S. L. J. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04446-8 · Cited by 4
“Hence, by encapsulating xanthone derivatives, nanocarriers potentially facilitate their delivery to the brain and improve the therapeutic efficacy of AD (Satapathy et al. 2021).”
Enhancing the therapeutical potential of metalloantibiotics using nano-based delivery systems
Llamedo, A., Cano, M., Soengas, R. G., & Alonso, F. J. G. (2025) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.16.98 · Cited by 5
Nano-boosted quercetin: A modern Chinese herb to overcome drug-resistant breast cancer
Vikal, A., & Maurya, R. (2025) · Next research. · doi:10.1016/j.nexres.2025.101053 · Cited by 3
Kothapalli, P., & Vasanthan, M. (2025) · BioNanoScience · doi:10.1007/s12668-025-02277-8 · Cited by 3
“…highest solubility for the drug was identified as having the maximum drug load - ing capacity and was subsequently selected for development of SLNs [30]. b. Apparent Partition coefficient (Pₐₚₚ) of the drug in different lipids: To further validate the lipid selection, the apparent partition…”
Adetuyi, B. O., & Vega, L. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_239 · Cited by 9
Mottaqi, M., Langarizadeh, M. A., Molaali, N., Rezaei, M., Ameri, A., & Forootanfar, H. (2024) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-024-00787-6 · Cited by 3
“Borneol has been chiefly employed as an adjuvant in traditional Chinese prescriptions to increase medication delivery to the brain and as a BBB permeability enhancer (Kulkarni et al. 2021).”
Sahu, S., Telegaonkar, S., & Mishra, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00002-0 · Cited by 3
Novel drug delivery systems in treating epilepsy: An update
Uppal, J., Chawla, A., Rehman, R., Hussain, M. S., Maqbool, M., Chawla, P. A., Mohi-ud-din, R., & Mir, R. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00019-6 · Cited by 3
Biomaterials in Clinical Trials and Clinical Applications
Madan, A., Saini, R., Satapathy, M. K., & Arora, D. (2025) · Springer eBooks · doi:10.1007/978-981-97-9959-6_9 · Cited by 5
Self-citationVarshini, M. S., Shanavas, S., Pindiprolu, S. S. S. K. S., Nagappan, K., More, S., Chaudhury, D., Reddy, R. A., Singh, M. T., Wadhwani, A., Bose, B., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00329 · Cited by 5
Solid Lipid Nanoparticles: A Nano Drug Carrying System in Treatment of Nervous Diseases
Yin, Y., Zhang, J., & Zhou, X. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v11i.1266 · Cited by 3
Envisioning the prospect of nanocarriers as an effective management tool against NeuroAIDS
Tyagi, S., Baboota, S., Gaikwad, S., Ali, J., Mukherjee, A., & Kumar, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105274 · Cited by 3
Pharmacokinetics and pharmacodynamics of various novel formulations targeting Alzheimer's disease
Gawade, A. R., Polshettiwar, S. A., Hingalajia, H., Prajapati, B. G., & Singh, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00027-3 · Cited by 4
Treatment of heavy metal induced neurotoxicity via advanced drug delivery systems
Kumar, A. J., Srivastava, A., Rachamalla, M., Ali, M., Navin, S., Kumar, D., & Ghosh, A. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00025-1 · Cited by 6
ApoE potential in CNS drugs targeting and as CNS therapeutic
Ahmed, S., Pande, A. H., & Sharma, S. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23841-3.00005-4 · Cited by 5
Babaei, A., Ebrahimi, H., Kouchaksaraei, T. S., Hamidi, S. M., Aliabad, M. K., Siahposht-Khachaki, A., & Ebrahimnejad, P. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2468758 · Cited by 3
“For instance, polysorbate (20, 60, 80)-coated slNs enhance BBB penetration by apolipoprotein-mediated endocytosis, demonstrating enhanced pharmacological efficacy [46].”
Bera, S., Ganguly, S. C., Manna, P., & Kundu, M. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115053 · Cited by 3
Material considerations for delivering therapeutics across the blood–brain barrier
Zoba, A. N., & Tringides, C. M. (2025) · APL Materials · doi:10.1063/5.0284305 · Cited by 2
Cutting-edge strategies for delivering drugs to the brain based on nanocarriers
Shaw, T. K., Shuvo, S. M., Paul, P., Jana, A., & Ali, K. A. (2025) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2025.2555858 · Cited by 2
Bakshi, V., & Fathima, B. (2025) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0066 · Cited by 6
From Bench to Brain: Translating EV and Nanocarrier Research into Parkinson’s Disease Therapies
Barathan, M., & Abdullah, N. A. H. (2025) · Biology · doi:10.3390/biology14101349 · Cited by 2
“On the other hand, IV administration of SLNs or NLCs, while offering systemic availability, is restricted by the dense BBB, normally leading to compromised CNS bioavailability and increased or multiple dosing, except that the carriers are surface-engineered to enhance brain uptake [186].”
da Silva, J. V. L., Silva, D. M. E., de Moraes, J., Tavares, G. D., & Filho, A. A. D. S. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2571018 · Cited by 3
Sadhu, P., Kumari, M., Shah, N. V., Shah, N., Talele, C., & Rathod, F. (2025) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2025.102873 · Cited by 2
Torres, J., Silva, R., Farias, G., Lobo, J. M. S., Ferreira, D. D. C., & Silva, A. C. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-025-00821-6 · Cited by 3
Metadata
- Authors
- Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H.
- Affiliations
- Taipei Medical University (TW)
- Cathay General Hospital (TW)
- Taipei Medical University Hospital (TW)
- Birla Institute of Technology and Science, Pilani (IN)
- Corresponding author
- Yang, Chih-Hao
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-07-31
- Volume
- 13
- Issue
- 8
- Pages
- 1183
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8402065
- OpenAlex
- W3187770666
- Cited by
- 318
- References
- 268
- Citations by year
- 2026: 64 · 2025: 95 · 2024: 70 · 2023: 55 · 2022: 30 · 2021: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-08-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (MOST-106-2320-B-038-049-MY3, MOST-108-2314-B-038-022)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- solid lipid nanoparticles, blood-brain barrier, brain drug delivery, central nervous system disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, brain tumors, epilepsy, ischemic stroke, nanoparticle synthesis, drug carriers, controlled drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.